Melatonergic agonist regulates circadian clock genes and peripheral inflammatory and neuroplasticity markers in patients with depression and anxiety
ConclusionRMT treatment is able to restore phase-shifted melatonin markers, normalized the altered expression of the circadian genes, the levels of inflammatory cytokines and neurotrophins in patients with insomnia comorbid anxiety and depression.
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
More News: Anxiety | Brain | Depression | Genetics | Insomnia | Melatonin | Neurology | Psychiatry | Sleep Disorders | Sleep Medicine | Study